glp-1 options for type 2 diabetes and obesity 2025 GLP-1RAs Reduce External Eating Behavior with GLP-1s in 2025: Who's Using

The injectable versus oral comparison helps clarify the tradeoffs between convenience and potency for various peptide therapies

Obesity (Silver Spring, Md) 2024;32(2):234236

GLP-1 Agonisten sind vielversprechende Wirkstoffe, um das Risiko des Fortschreitens einer chronischen Lebererkrankung bei Patienten mit gleichzeitigem T2DM zu verringern (19)

Evidence-based guides, dosing tools, treatment comparisons, and a community of thousands who have navigated these exact questions make it the go-to platform for peptide education and support

Holst 2007)

The STEP 1 extension data showed maintained weight loss at 104 weeks, with participants maintaining an average 13.7% weight reduction from baseline